$SLBT

SL Science Holding Ltd

SL Science is a biomedical holding company headquartered in Taipei, Taiwan, that conducts its business through subsidiary SL Bio. It develops cellular and gene therapies, with programs including CD-19 Armed-T therapy for blood cancers and Gamma Delta T cell therapies for pancreatic and brain cancers. Its platforms use engineered immune cells and expanded donor-derived cells; development activities include product design, testing, and manufacturing process work. The products are in preclinical development. SL Science also has legacy exosome cosmetics and plant supplement businesses. Its business model centers on developing partnerships with biopharmaceutical companies to advance technologies into drugs and cancer treatments, using licensing and collaborations with technology providers and academic and clinical partners. Its licenses cover Armed-T and Gamma Delta T technologies, and it is obligated to pay royalties on sales of licensed products.

No enriched coverage for $SLBT in the last 7 days.

No SEC Form 4 filings for $SLBT in the last 30 days.

See all $SLBT insider activity →
Med

SL Science Reports Higher Revenue, Expands Gross Margin In First Half 2026

SL Science Holding Limited (SLBT) reported a 23% revenue increase to $1.39M for H1 2026, with gross margin expanding to 40.2%. Costs rose, leading to a wider net loss of $2.16M. The company completed its Nasdaq listing and advanced its cell therapy programs, including FDA filings and a PIPE financing of $7.8M. SLBT closed at $1.23, up 6.96%.

SL Science Holding Ltd (SLBT): Financial results for H1 2026

SL Science Holding Ltd (SLBT) furnished an SEC Form 6-K — earnings release. Exhibit 99.3 SL Science Holding Limited Reports First Half 2026 Financial Results Net revenue rose 23% to $1.39 million with gross margin expanding to 40.2%, driven by B2B distribution growth and reduction in purchase costs compared with last period due to establishment of stable

SLBT sentiment & insider activity

Recent SLBT coverage spans earnings, regulation and market movers.

What's driving SLBT

AlphAI scores every news story that mentions SLBT with an AI model for sentiment and relevance, and aggregates insider trades from SL Science Holding Ltd's SEC EDGAR Form 4 filings. Figures refresh continuously.

News on $SLBT

Score
$SLBTMedEarnings

SL Science Holding Ltd (SLBT): Financial results for H1 2026

SL Science Holding Ltd (SLBT) furnished an SEC Form 6-K — earnings release. Exhibit 99.3 SL Science Holding Limited Reports First Half 2026 Financial Results Net revenue rose 23% to $1.39 million with gross margin expanding to 40.2%, driven by B2B distribution growth and reduction in purchase costs compared with last period due to establishment of stable

SL Science Holding Limited: SL Science Highlights New FDA Drug Master File for GDT Cell-Derived Exosomes, Expanding the Regulatory Foundation of its Platform

SL Science (NASDAQ: SLBT) announced that JY BioMed filed a new FDA Drug Master File (DMF) for GDT cell-derived exosomes, expanding regulatory documentation. This milestone covers exosomes and GDT cells, potentially streamlining future regulatory processes. The exosomes may address delivery challenges in oncology, including crossing the blood-brain barrier for brain cancer treatment.

Top Biotech Gainers: UPC Cuts Loss, CPIX Gains Ahead Of Q2 Results, AUTL Builds Commercial Momentum

Biotech gainers on Monday included Universe Pharmaceuticals (UPC), which reported six-month ended March 31, 2026 revenue of $9.03 million and net loss of $1.55 million, and shares rose about 99% to $6.48. Cumberland Pharma (CPIX) rose over 38% ahead of Q2 results after a $100 million branded portfolio sale. Autolus (AUTL) gained about 22% on preliminary Q2 Aucatzyl net product revenue of about $45 million. Other movers included Pulmonx (LUNG), SL Science (SLBT), CAMP4 (CAMP), and Beyond Air (XAI

Related tickers